Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03SKC
|
||||
| Former ID |
DNCL002876
|
||||
| Drug Name |
KRP-104
|
||||
| Synonyms |
Antigen inhibitor
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [1] | ||
| Company |
ActivX Biosciences
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | Modulator | [2] | |
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00525330) A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Activx. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.